메뉴 건너뛰기




Volumn 105, Issue 1, 2011, Pages 44-52

Phase i dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

Author keywords

antiangiogenesis; brivanib; cetuximab; gastrointestinal tumours

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; BRIVANIB ALANINATE; CETUXIMAB; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; K RAS PROTEIN; MITOMYCIN C;

EID: 79959699570     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.182     Document Type: Article
Times cited : (30)

References (24)
  • 1
    • 79959752853 scopus 로고    scopus 로고
    • Anti-angiogenic therapy using brivanib, a combined VEGF and FGF pathway inhibitor, in a mouse model of pancreatic neuroendocrine cancer (PNET), results in sustained vascular blockade, without evidence for evasive/acquired resistance in the form of VEGF-independent revascularization, in contrast to other VEGF inhibitors [abstract]
    • Allen E, Walters IB, Rivera IC, Hanahan D (2009) Anti-angiogenic therapy using brivanib, a combined VEGF and FGF pathway inhibitor, in a mouse model of pancreatic neuroendocrine cancer (PNET), results in sustained vascular blockade, without evidence for evasive/acquired resistance in the form of VEGF-independent revascularization, in contrast to other VEGF inhibitors [abstract]. Mol Cancer Ther 8(Suppl 12): B16
    • (2009) Mol Cancer Ther , vol.8 , Issue.SUPPL. 12
    • Allen, E.1    Walters, I.B.2    Rivera, I.C.3    Hanahan, D.4
  • 2
    • 47949099628 scopus 로고    scopus 로고
    • Modes of resistance to anti-angiogenic therapy
    • Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8): 592-603
    • (2008) Nat Rev Cancer , vol.8 , Issue.8 , pp. 592-603
    • Bergers, G.1    Hanahan, D.2
  • 7
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
    • DOI 10.1200/JCO.2006.09.6305
    • Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson III AB (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12): 1539-1544 (Pubitemid 46733080)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.12 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3    O'Dwyer, P.J.4    Mitchell, E.P.5    Alberts, S.R.6    Schwartz, M.A.7    Benson III, A.B.8
  • 10
    • 58149175849 scopus 로고    scopus 로고
    • Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma
    • Huynh H, Ngo VC, Fargnoli J, Ayers M, Soreide O, Koong HN, Thng CH, Ong HS, Chow P, Pollock P, Byron S, Tran E (2008) Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14: 6146-6153
    • (2008) Clin Cancer Res , vol.14 , pp. 6146-6153
    • Huynh, H.1    Ngo, V.C.2    Fargnoli, J.3    Ayers, M.4    Soreide, O.5    Koong, H.N.6    Thng, C.H.7    Ong, H.S.8    Chow, P.9    Pollock, P.10    Byron, S.11    Tran, E.12
  • 13
    • 0037208589 scopus 로고    scopus 로고
    • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    • Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1): 60-65
    • (2003) J Clin Oncol , vol.21 , Issue.1 , pp. 60-65
    • Kabbinavar, F.1    Hurwitz, H.I.2    Fehrenbacher, L.3    Meropol, N.J.4    Novotny, W.F.5    Lieberman, G.6    Griffing, S.7    Bergsland, E.8
  • 16
    • 43249095919 scopus 로고    scopus 로고
    • Tumor angiogenesis
    • DOI 10.1056/NEJMra0706596
    • Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19): 2039-2049 (Pubitemid 351656458)
    • (2008) New England Journal of Medicine , vol.358 , Issue.19 , pp. 2039-2049
    • Kerbel, R.S.1
  • 23
    • 70349650689 scopus 로고    scopus 로고
    • Repeatability of 18F-FDG PET in a multicenter phase i study of patients with advanced gastrointestinal malignancies
    • Velasquez LM, Boellaard R, Kollia G, Hayes W, Hoekstra OS, Lammertsma AA, Galbraith SM (2009) Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med 50(10): 1646-1654
    • (2009) J Nucl Med , vol.50 , Issue.10 , pp. 1646-1654
    • Velasquez, L.M.1    Boellaard, R.2    Kollia, G.3    Hayes, W.4    Hoekstra, O.S.5    Lammertsma, A.A.6    Galbraith, S.M.7
  • 24
    • 0032757213 scopus 로고    scopus 로고
    • 18F]- fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations
    • DOI 10.1016/S0959-8049(99)00229-4, PII S0959804999002294
    • Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35(13): 1773-1782 (Pubitemid 29512308)
    • (1999) European Journal of Cancer , vol.35 , Issue.13 , pp. 1773-1782
    • Young, H.1    Baum, R.2    Cremerius, U.3    Herholz, K.4    Hoekstra, O.5    Lammertsma, A.A.6    Pruim, J.7    Price, P.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.